顺铂对哺乳动物前庭终器的差异性损伤
该研究在小鼠多周期顺铂模型中系统评估前庭功能与形态,发现前庭诱发电位阈值在停药后即刻升高并持续恶化至6个月,球囊毛细胞显著减少而椭圆囊和水平半规管不受累,提示球囊对顺铂独特易感,建议监测耳石功能。
要点
- 顺铂可致前庭诱发电位阈值升高并在停药后6个月继续恶化。
- 球囊毛细胞显著减少,椭圆囊和水平半规管形态正常。
- 耳石传入低失真比例下降,提示平移反应精确性降低。
核心结论
- 顺铂对前庭终器有差异性损伤,球囊在小鼠模型中独特易感。
- 停药后前庭功能障碍可能继续恶化,建议监测耳石功能。
研究设计与样本
- 在给药前、末次周期后及停药6个月后进行前庭感觉诱发电位测试,停药6个月后进行前庭眼反射和传入单位记录,随后解剖椭圆囊、球囊和水平半规管进行形态学检查。
- 另回顾人颞骨组织病理报告以对照临床证据。
主要发现
- 顺铂组前庭感觉诱发电位阈值在停药后即刻显著升高,6个月后进一步恶化。
- 旋转和平移前庭眼反射一般不受顺铂影响。
- 半规管传入自发放电率无显著变化,但整体规律性显著下降。
- 耳石传入自发放电率和规律性无显著差异,但低失真耳石传入比例显著降低。
- 球囊毛细胞数量显著减少,椭圆囊和水平半规管无显著减少;一份高累积顺铂患者颞骨报告仅见球囊退变。
临床怎么用
- 对接受顺铂治疗的患者应考虑监测耳石功能以筛查前庭毒性。
- 停药后仍需关注前庭功能可能继续恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cisplatin is an effective anticancer drug that can induce cochleotoxicity in up to 50 to 60% of treated patients. However, the vestibulotoxic potential of cisplatin remains unclear. Our lab previously developed a multicycle model of cisplatin administration in mice that results in hearing loss similar to that observed clinically. The purpose of this study was to comprehensively characterize the functional and morphological consequences of cisplatin on the vestibular periphery in this mouse model. DESIGN: Twenty-nine adult CBA/CaJ mice were assigned to control or cisplatin-treated groups. Cisplatin-treated mice received three consecutive cycles of once-daily cisplatin for 4 days followed by a 10-day recovery period. Mice underwent vestibular sensory evoked potential testing before cisplatin administration, after the final cycle of cisplatin, and 6 mo after treatment cessation. Mice also underwent vestibulo-ocular reflex testing and vestibular afferent single-unit recordings 6 mo after treatment cessation. Following testing, utricles, saccules, and horizontal semicircular canals were microdissected, and vestibular morphology was examined. To examine whether our data in mice were consistent with reports of cisplatin-induced vestibulotoxicity in patients, histopathology reports of human temporal bones were examined for evidence of cisplatin-induced vestibulotoxicity. RESULTS: Vestibular sensory evoked potential thresholds were significantly elevated in cisplatin-treated mice immediately after cessation of cisplatin administration and progressively worsened 6 mo later. Rotational and translational vestibulo-ocular reflexes were generally unaffected by cisplatin. Cisplatin did not cause statistically significant changes in the spontaneous firing rates of semicircular canal afferents but did cause significant decreases in their overall regularity. No statistically significant differences in the spontaneous firing rates or regularity of otolith afferents were observed. However, cisplatin-treated mice exhibited statistically significant decreases in the percentage of low-distortion otolith afferents, indicating that responses of these afferents to head translations were more variable and less precise. Cisplatin-treated mice showed significantly decreased hair cell numbers in the saccule but not in the utricle or horizontal semicircular canal. One temporal bone histopathology report from an individual treated with high cumulative cisplatin was consistent with the results of our study, showing only saccular degeneration with normal utricle and semicircular canal morphology. CONCLUSIONS: Our study demonstrates cisplatin's potential to affect the vestibular end organs adversely and differentially. The saccule was uniquely susceptible in our mouse model, suggesting that it may be possible to screen for cisplatin-induced vestibulotoxicity by testing saccular function. While very little is known about the potential for progression of cisplatin-induced vestibulotoxicity, our results suggest vestibular dysfunction may continue to worsen after cessation of cisplatin treatment. We recommend that ongoing and future efforts at evaluating vestibular function in patients treated with cisplatin include monitoring and evaluation of otolith function.
引用
- Lee J, Zhu H, Zhou W, et al. Cisplatin Differentially Damages Mammalian Vestibular End Organs. Ear Hear. 2025. PMID: 41469892. doi:10.1097/AUD.0000000000001772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。